Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 3—March 2025
CME ACTIVITY - Research

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes

Ekaterina V. KurbatovaComments to Author , William C. Whitworth, Lakshmi Praveena Peddareddy, Patrick P.J. Phillips, Nigel A. Scott, Kia E. Bryant, Rodney Dawson, Sandra Wagner Cardoso, Wadzanai Samaneka, Melissa Engle, Ziyaad Waja, Erin Sizemore, Wendy Carr, Kelly E. Dooley, Radojka Savic, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, Payam Nahid, Nhung V. Nguyen, and AIDS Clinical Trials Group A5349,1 and Tuberculosis Trials Consortium Study 312
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, W.C. Whitworth, L.P. Peddareddy, N.A. Scott, K.E. Bryant, E. Sizemore, W. Carr); University of California– San Francisco Center for Tuberculosis, San Francisco, California, USA (P.P.J. Phillips, R. Savic, P. Nahid); University of Cape Town Lung Institute, Cape Town, South Africa (R. Dawson); Fundação Oswaldo Cruz Insituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil (S. Wagner Cardoso); Milton Park Clinical Research Site, Harare, Zimbabwe (W. Samaneka); Audie L. Murphy Veterans Administration Medical Center, San Antonio, Texas, USA (M. Engle); Wits Health Consortium Perinatal HIV Research Unit, Johannesburg, South Africa (Z. Waja); Vanderbilt University Medical Center, Nashville, Tennessee, USA (K.E. Dooley); University of Nebraska Medical Center, Omaha, Nebraska, USA (S. Swindells); Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (R.E. Chaisson); Medical University of South Carolina, Charleston, South Carolina, USA (S.E. Dorman); Vietnam National Tuberculosis Program/University of California–San Francisco Research Collaboration Unit, Hanoi, Vietnam (N.V. Nguyen)

Main Article

Figure 2

Analysis of time to sputum culture conversion (number of weeks from randomization) in liquid (A) and solid media (B) among participants with diabetes, by tuberculosis drug regimen, in the microbiologically eligible analysis population in a study assessing efficacy and safety of 4-month rifapentine-based tuberculosis treatments in persons with diabetes at sites in 12 countries (Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, United States, Vietnam, and Zimbabwe), January 2016–October 2018. Because scheduled study visits did not necessarily occur exactly at 8 weeks, the proportion of participants with culture conversion at 8 weeks is estimated from the Kaplan-Meier estimator at t = 10 weeks. Differences were not statistically significant for any comparisons.

Figure 2. Analysis of time to sputum culture conversion (number of weeks from randomization) in liquid (A) and solid media (B) among participants with diabetes, by tuberculosis drug regimen, in the microbiologically eligible analysis population in a study assessing efficacy and safety of 4-month rifapentine-based tuberculosis treatments in persons with diabetes at sites in 12 countries (Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, United States, Vietnam, and Zimbabwe), January 2016–October 2018. Because scheduled study visits did not necessarily occur exactly at 8 weeks, the proportion of participants with culture conversion at 8 weeks is estimated from the Kaplan-Meier estimator at t = 10 weeks. Differences were not statistically significant for any comparisons.

Main Article

1Members of group listed at the end of this article.

2Members of group listed at the end of this article.

Page created: January 15, 2025
Page updated: February 24, 2025
Page reviewed: February 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external